AC Immune Reveals Pioneering Neurodegenerative Drug Technology
Company Announcements

AC Immune Reveals Pioneering Neurodegenerative Drug Technology

AC Immune SA (ACIU) has released an update.

AC Immune SA has introduced a groundbreaking antibody drug conjugate (ADC) technology, named morADC, at the Alzheimer’s Association International Conference, showcasing its potential to revolutionize treatment for neurodegenerative diseases. This novel technology leverages the company’s proprietary Morphomer small molecules and SupraAntigen monoclonal antibodies to create drug-candidates with enhanced brain penetration and potency against toxic proteins in the central nervous system. The morADC platform promises to offer unique, synergistic benefits, potentially overcoming limitations of current treatments and advancing precision medicine in neurodegenerative conditions.

For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAC Immune SA Reports Profitable Q3 2024 Results
TheFlyAC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year
TipRanks Auto-Generated NewsdeskAC Immune SA Welcomes New CMO Dr. Anke Post
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App